Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BOPH OTCMKTS:HSTC OTCMKTS:NRXGQ NASDAQ:OBSV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOPHBohai Pharmaceuticals Group$0.00$0.00$0.00▼$0.00$20K1.7830,425 shs50,000 shsHSTCHST Global$0.00$0.10$0.00▼$1.05$14K-1.4935 shsN/ANRXGQNephroGenex$0.00$0.00▼$0.21$36KN/A26,223 shs2,000 shsOBSVObsEva$0.00$0.00$0.08▼$2.14$39K0.688.94 million shsN/ABeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOPHBohai Pharmaceuticals Group0.00%0.00%0.00%0.00%0.00%HSTCHST Global0.00%0.00%-50.00%-99.98%-99.98%NRXGQNephroGenex0.00%0.00%0.00%0.00%0.00%OBSVObsEva0.00%0.00%0.00%-75.00%-75.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOPHBohai Pharmaceuticals GroupN/AN/AN/AN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOPHBohai Pharmaceuticals Group 0.00N/AN/AN/AHSTCHST Global 0.00N/AN/AN/ANRXGQNephroGenex 0.00N/AN/AN/AOBSVObsEva 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOPHBohai Pharmaceuticals GroupN/AN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOPHBohai Pharmaceuticals GroupN/AN/A0.00∞N/AN/AN/AN/AN/AHSTCHST Global-$150K-$0.02N/A∞N/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/A0.00N/AN/AN/AN/AN/AN/AOBSVObsEva-$58.38M-$0.92N/A∞N/AN/A-416.36%-92.01%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOPHBohai Pharmaceuticals GroupN/AN/AN/AN/AN/AHSTCHST GlobalN/AN/AN/AN/AN/ANRXGQNephroGenexN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOPHBohai Pharmaceuticals GroupN/AN/AN/AHSTCHST GlobalN/AN/AN/ANRXGQNephroGenexN/AN/AN/AOBSVObsEvaN/A0.610.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOPHBohai Pharmaceuticals GroupN/AHSTCHST GlobalN/ANRXGQNephroGenexN/AOBSVObsEva17.52%Insider OwnershipCompanyInsider OwnershipBOPHBohai Pharmaceuticals GroupN/AHSTCHST Global65.82%NRXGQNephroGenexN/AOBSVObsEva14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOPHBohai Pharmaceuticals GroupN/A19.52 millionN/ANot OptionableHSTCHST Global170.19 million23.99 millionNot OptionableNRXGQNephroGenex1,70012.95 millionN/ANot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableHSTC, OBSV, NRXGQ, and BOPH HeadlinesRecent News About These CompaniesNabriva Therapeutics (NASDAQ:NBRV) vs. ObsEva (NASDAQ:OBSV) Head-To-Head AnalysisAugust 31 at 2:16 AM | americanbankingnews.comObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantAugust 31, 2024 | pharmaphorum.comPObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of ListinApril 3, 2024 | globenewswire.comObsEva Announces Update on Board of DirectorsMarch 19, 2024 | globenewswire.comObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023February 28, 2024 | globenewswire.comObsEva Stock (OTC:OBSEF) Dividends: History, Yield and DatesFebruary 25, 2024 | benzinga.comObsEva SA OBSNNovember 11, 2023 | morningstar.comMObsEva SA OBSEFNovember 11, 2023 | morningstar.comMObsEva (NASDAQ: OBSV)June 18, 2023 | fool.comTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserverMay 10, 2023 | news.google.comNObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo FinanceMay 2, 2023 | news.google.comNObsEva Says Fabien De Ladonchamps Is New CEO - NasdaqMay 2, 2023 | news.google.comNObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswireMay 2, 2023 | news.google.comNGameto Appoints Teri Loxam as Chief Financial Officer - citybizApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - Marketscreener.comApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - Yahoo FinanceApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - BenzingaApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - EIN NewsApril 28, 2023 | news.google.comNGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR NewswireApril 28, 2023 | news.google.comNEndometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital JournalApril 26, 2023 | news.google.comNHSTC, OBSV, NRXGQ, and BOPH Company DescriptionsBohai Pharmaceuticals Group OTCMKTS:BOPH$0.0010 0.00 (0.00%) As of 03/11/2019Bohai Pharmaceuticals Group, Inc. engages in the production, manufacture, and distribution of herbal pharmaceuticals based on traditional Chinese medicine. Its products include lung nourishing syrup, tongbi capsules, tongbi tablets, zhuangyuanshenhailong medicinal wine, bazhenyimu cream, fangfengtongsheng granule, and zhengxintai capsules. The company was founded on January 9, 2008 and is headquartered in Yantai, China.HST Global OTCMKTS:HSTC$0.0002 0.00 (0.00%) As of 09/2/2025HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.NephroGenex OTCMKTS:NRXGQNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.ObsEva NASDAQ:OBSV$0.0005 0.00 (0.00%) As of 09/2/2025ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
